BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

512 related articles for article (PubMed ID: 19570087)

  • 1. Efficacy of glucantime in the treatment of Old World cutaneous leishmaniasis.
    Firdous R; Yasinzai M; Ranja K
    Int J Dermatol; 2009 Jul; 48(7):758-62. PubMed ID: 19570087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative study of the efficacy of oral ketoconazole with intra-lesional meglumine antimoniate (Glucantime) for the treatment of cutaneous leishmaniasis.
    Salmanpour R; Handjani F; Nouhpisheh MK
    J Dermatolog Treat; 2001 Sep; 12(3):159-62. PubMed ID: 12243707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis.
    Sadeghian G; Nilforoushzadeh MA
    Int J Dermatol; 2006 Jul; 45(7):819-21. PubMed ID: 16863518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A
    J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis.
    Nilforoushzadeh MA; Jaffary F; Moradi S; Derakhshan R; Haftbaradaran E
    BMC Complement Altern Med; 2007 Apr; 7():13. PubMed ID: 17466071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis.
    Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD
    Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful treatment of non-healing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol.
    Momeni AZ; Aminjavaheri M
    Eur J Dermatol; 2003; 13(1):40-3. PubMed ID: 12609780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized clinical trial comparing oral azithromycin and meglumine antimoniate for the treatment of American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis.
    Krolewiecki AJ; Romero HD; Cajal SP; Abraham D; Mimori T; Matsumoto T; Juarez M; Taranto NJ
    Am J Trop Med Hyg; 2007 Oct; 77(4):640-6. PubMed ID: 17978064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis.
    Soto J; Toledo J; Vega J; Berman J
    Am J Trop Med Hyg; 2005 Apr; 72(4):421-2. PubMed ID: 15827279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of CO laser efficacy in the treatment of cutaneous leishmaniasis.
    Asilian A; Sharif A; Faghihi G; Enshaeieh Sh; Shariati F; Siadat AH
    Int J Dermatol; 2004 Oct; 43(10):736-8. PubMed ID: 15485530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allopurinol in the treatment of American cutaneous leishmaniasis.
    Martinez S; Marr JJ
    N Engl J Med; 1992 Mar; 326(11):741-4. PubMed ID: 1738379
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.
    Armijos RX; Weigel MM; Calvopiña M; Mancheno M; Rodriguez R
    Acta Trop; 2004 Jul; 91(2):153-60. PubMed ID: 15234664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Thymus vulgaris (Thyme), Achillea millefolium (Yarrow) and propolis hydroalcoholic extracts versus systemic glucantime in the treatment of cutaneous leishmaniasis in balb/c mice.
    Nilforoushzadeh MA; Shirani-Bidabadi L; Zolfaghari-Baghbaderani A; Saberi S; Siadat AH; Mahmoudi M
    J Vector Borne Dis; 2008 Dec; 45(4):301-6. PubMed ID: 19248657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
    Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
    Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy of intramuscular meglumine antimoniate alone and in combination with intralesional meglumine antimoniate in the treatment of old world cutaneous leishmaniasis.
    Munir A; Janjua SA; Hussain I
    Acta Dermatovenerol Croat; 2008; 16(2):60-4. PubMed ID: 18541100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Both combined oral azithromycin plus allopurinol and intramuscular Glucantime yield low efficacy in the treatment of Old World cutaneous leishmaniasis: a randomized controlled clinical trial.
    Dastgheib L; Naseri M; Mirashe Z
    Int J Dermatol; 2012 Dec; 51(12):1508-11. PubMed ID: 23171020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the efficiency of topical paromomycin with intralesional meglumine antimoniate for cutaneous leishmaniasis.
    Moosavi Z; Nakhli A; Rassaii S
    Int J Dermatol; 2005 Dec; 44(12):1064-5. PubMed ID: 16409282
    [No Abstract]   [Full Text] [Related]  

  • 20. Current treatment for cutaneous leishmaniasis: a review.
    Palumbo E
    Am J Ther; 2009; 16(2):178-82. PubMed ID: 19300044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.